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Targeting the mitochondrial permeability transition 
pore in traumatic central nervous system injury
Introduction
The ability of cells in the central nervous system (CNS) to 
survive and maintain a functional level of homeostasis fol-
lowing a traumatic injury depends on a number of critical 
factors. At a relatively gross level, the type of insult (vascular, 
structural, etc.) as well as the severity and proximity of cells to 
the injury site are obvious factors. However, many pathophys-
iological events occur at the subcellular and molecular levels 
that ultimately determine cellular demise or recovery. These 
events have been well studied and include, but are not limited 
to, glutamate excitotoxicity, Ca2+ overload, inflammation, free 
radical mediated oxidative damage, and a loss of mitochon-
drial bioenergetics. Some of these secondary injury events are 
intimately interconnected, which is one rationale for develop-
ing neuroprotective therapeutic strategies targeting cell death 
signaling pathways at the molecular and cellular level.
The Mitochondrial Permeability Transition
Our research has focused on characterizing changes in mi-
tochondrial function after spinal cord (SCI) and traumatic 
brain (TBI) injuries (Sullivan et al., 2005; McEwen et al., 
2011). This is based on well-documented observations that 
mitochondria play a critical role in determining cellular 
fate, and compromised mitochondrial function is a prom-
inent feature in both SCI and TBI. Under physiological 
conditions, mitochondria exhibit a high transmembrane 
potential generated by the proton pumping components of 
the respiratory electron transport system. This transmem-
brane potential is a driving force in the phosphorylation of 
adenosine diphosphate (ADP) and sequestering Ca2+ from 
the cytosol. However, following SCI or TBI, mitochondria 
rapidly become dysfunctional resulting in a loss of cytosolic 
Ca2+ buffering capacity due to influx of massive pathophysi-
ological levels of Ca2+ through glutamate receptor subtypes, 
free radical mediated oxidative damage to mitochondrial 
complex proteins, and a subsequent compromise in bioen-
ergetic capacity. This process becomes insidious as the loss 
of energy production further reduces the ability of adenosine 
triphosphate (ATP)-dependent Ca2+ channels to regulate 
Ca2+ cytosolic levels. Prolonged Ca2+ overload can push mito-
chondria to the next pathophysiological stage- induction of 
the mitochondrial permeability transition (mPT) state due to 
mPT pore (mPTP) formation (Halestrap and Brenner, 2003). 
The mPT state uncouples respiration from ATP production 
and by this point recovery of mitochondrial function is limit-
ed at best. Cell survival is then compromised when sufficient 
numbers of mitochondria undergo mPT. Given the impor-
tance of mitochondria in cellular function, inhibiting forma-
tion of the mPTP is a strategy for limiting cell death in both 
SCI and TBI. In this perspective article, we summarize what 
is known about the mPTP and discuss the possible pros and 
cons of targeting the mPTP as a therapeutic strategy in CNS 
injury.
The mPTP is a multiprotein mega-channel complex span-
ning both the inner and outer mitochondrial membranes, 
essentially allowing for communication of small molecules 
between the matrix and cytosol. The structural components 
of the pore are not well understood and the subject of con-
tinuing debate. Initial studies suggested that the pore was 
made up of the voltage-dependent anion channel (VDAC) 
located on the outer mitochondrial membrane, the adenine 
nucleotide translocator (ANT) on the inner mitochondrial 
membrane, and cyclophilin-D (Cyp-D) in the matrix (Hal-
estrap and Brenner, 2003). However, follow-up genetic dele-
tion studies revealed that ANT and VDAC are not required 
for mPTP formation, which may be explained, in part, by 
the presence of different isoforms of these putative pore 
components (Bernardi et al., 2015). Despite these observa-
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tions, there is a general consensus that Cyp-D functions as a 
major contributor to mPTP formation.
Inhibiting mPTP Formation in TBI and SCI
Cyclosporine A (CsA) is an immunosuppressant that inhib-
its mPT by binding to Cyp-D. It has been shown repeatedly 
to be neuroprotective in TBI, although similar effects in 
SCI remain controversial based on conflicting reports. This 
differential efficacy of CsA in TBI versus SCI may be relat-
ed to properties inherent to mitochondria in the respective 
CNS regions. Moreover, it is difficult to examine a wide 
dose range of CsA due to its potent side effects and poten-
tial toxicity. In fact, doses of CsA above 20 mg/kg were, 
for the most part, ineffective in providing neuroprotection 
following TBI. Given these caveats, our group started inves-
tigating the use of NIM811, a Cyp-D binding CsA derivate 
lacking any immunosuppressive properties and having rel-
atively minimal toxicity (Waldmeier et al., 2002). Our early 
studies provided evidence that NIM811 reduces oxidative 
damage while improving mitochondrial function and tissue 
sparing following TBI or SCI (McEwen et al., 2007; Mbye 
et al., 2008). The outcome of these studies provided strong 
evidence that NIM811 and CsA exhibited neuroprotective 
effects by inhibiting mPTP formation. A recent report by 
our group revealed a dose dependent effect of post-injury 
NIM811 treatment in experimental SCI (Springer et al., 
2018). Interestingly, we observed that a low dose of NIM811 
significantly improved locomotor recovery, while higher 
doses significantly increased tissue sparing and reflexive 
bladder control but not recovery of locomotor function. The 
reasons for these dose-related differences are not clear at 
this time, although it can be suggested that conducting a fol-
low-up study examining additional doses in the range used 
in this study might prove revealing.
As stated above, there is strong evidence that targeting the 
mPTP has therapeutic potential in the treatment of TBI and 
Table 1 Experimental studies testing the efficacy of CsA or NIM811 in the treatment of TBI
Study TBI model/species Route Dose/time Outcome
Okonkwo et al. (1999) IA/rat i.t. 10 mg/kg CsA/30 minutes pre-injury Decreased calpain-induced neurofilament 
compaction and cytokeletal damage
Okonkwo and 
Povlishock (1999)
IA/rat i.t. 10 mg/kg CsA/30 minutes pre-injury Preserves mitochondrial morphology and prevents 
axonal failure
Büki et al. (1999) IA/rat i.t. 10 mg/kg CsA/30 minutes post-injury Decreases in neurofilament compaction, calpain 
activity and amyloid precursor protein (APP) 
accumulation
Scheff and Sullivan 
(1999)
CCI/rat and mice i.p. FK506: 40 or 20 mg/kg 5 minutes post- 
injury + 24 hours post-injury. CsA: 20, 40, 
or 150 mg/kg 5 minutes pre-injury
Improvement in cortical sparing with CsA but not 
FK-506
Sullivan et al. (1999) CCI/rat i.p. 20 mg/kg CsA 15 minutes post-injury Preservation of mitochondrial function and 
decreased free radical production.
Fukui et al. (2003) CCI/rat i.v. 20 or 35 mg/kg CsA 1 hour infusion at 30 
minutes post-injury
No significant change in brain water content
Signoretti et al. (2004) IA/rat i.t. and i.v. (1) i.t. 10 mg/kg 30 minutes post-injury 
(2) i.v. 20 mg/kg 30 minutes post-injury
(3) i.v. 35 mg/kg 30 minutes post-injury
Adenosine triphosphate (ATP) levels restored in i.t. 
and 35 mg/kg i.v. CsA administration groups
Gabbita et al. (2005) CCI/rat i.p. 20 mg/kg CsA 15 minutes + 24 hours post- 
injury
Significant decrease in hippocampal tau protein 
degradation
Turkoglu et al. (2010) Contusion/rat i.p./cortical 
implant
20 mg/kg CsA at time of injury 10 mg/kg 
CsA in microsphere formulation
Implantation of microsphere formulation improves 
mitochondrial integrity
Colley et al. (2010) FPI/rat i.p. 20 mg/kg CsA 15 minutes or 1 hour post- 
injury
Significant neuroprotection for myelinated axons.
Sullivan et al. (2011) CCI/rat i.p./pump 20 mg/kg CsA/i.p./1–8 hours post + pump 
10 mg/kg/day
Neuroprotection was observed when CsA started 
within 8 hours post-injury
Readnower et al. (2011) CCI/rat oral NIM811: 5–40 mg/kg/15 minutes and 24 
hours post-injury 
NIM811: 10 mg/kg/15 minutes and 24 
hours post-injury
NIM811 (10 mg/kg) improves mitochondrial 
function, and reduces oxidative at 6 hours post-
injury, and improves cognition 10 days post-injury
Kilbaugh et al. (2011) CCI/rat IA/piglet i.p. Rat: 20 mg/kg/CsA/15 minutes post-injury 
Piglet: 20 mg/kg/CsA/5 minutes and 12 
hours post-injury
CsA improves mitochondrial function, preserves 
cerebral blood flow, and limits neuropathology
Dixon et al. (2016) FPI/CCI/PBBI/rat i.v. CsA:10 or 20 mg/kg 15 minutes and 24 
hours post-injury
No protective/functional effect of CsA on any 
measure
Kulbe et al. (2017) CCI/rat i.p. 20 mg/kg/CsA/15 minutes post-injury Improve synaptic and non-synaptic mitochondrial 
respiration
Kulbe et al. (2018) CCI/rat i.p./pump CsA: 20 mg/kg/CsA/15 minutes post- 
injury + pump: 10 mg/kg/day/3 days 
Phenelzine (PZ): 10 mg/kg/CsA/15 
minutes post-injury + pump: 
10 mg/kg/day/3 days
PZ and CsA together enhance neuroprotection
CCI: Controlled cortical impact; TBI: traumatic brain injury; CsA: cyclosporin A; FPI: fluid percussion injury; IA: inertial acceleration; i.p.: 
intraperitoneal; i.t.: intrathecal; i.v.: intravenous; PBBI: penetrating ballistic-like brain injury.
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SCI and numerous studies have examined this hypothesis 
with mixed results. We conducted a PubMed search to iden-
tify published studies investigating CsA or NIM811 in either 
TBI or SCI and the results of this search are summarized in 
Tables 1 and 2, respectively. What is clear from this analysis 
is that the many labs found CsA or NIM811 to be effective 
in the treatment of various TBI-related outcomes across a 
range of doses, routes of administration and injury models. 
NIM811 was reported to be effective in one TBI study while 
all but two studies (see Fukui et al. (2003) and Dixon et al. 
(2016) in Table 1) reported structural, physiological, or 
functional efficacy with CsA treatment. It is interesting to 
point out that these two negative outcome studies used an 
intravenous route of delivery, while the positive outcome 
studies employed intrathecal, subcutaneous or intraperito-
neal routes of administration. Given the pharmacokinetics, 
clearance rates, etc., associated with different routes of ad-
ministration, it is possible to speculate that an intravenous 
route may not be optimal. One of these studies (Fukui et al., 
2003) recommended that another route of administration 
be considered as there was no effect of intravenous CsA 
administration at least in terms of reducing brain edema. 
In addition, we have avoided an intravenous route of ad-
ministration in our TBI and SCI studies due to the relative 
toxicity of the vehicle. However, the results of a prospective 
randomized clinical trial indicate a good safety profile when 
using intravenous CsA administration in severe TBI patients 
(Mazzeo et al., 2009). 
CsA treatment in compression, contusion, or transec-
tion models of SCI has been reported to be either effective 
or ineffective in promoting functional recovery and tissue 
sparing (see Table 2). For example, work from Ibarra and 
colleagues report that CsA reduces lipid peroxidation, in-
creases survival of rubrospinal tract axons, and improves 
functional recovery, while Rabchevsky et al. (2001) report 
no effect of CsA treatment on any outcome measure in-
cluding functional recovery, tissue sparing. The reason for 
the discrepancies is not entirely clear, but may be related to 
differences in the injury models, injury severities, dosing, 
and routes of administration. We also demonstrated that the 
Cyp-D and oxidative stress levels are higher in uninjured 
spinal cord relative to cortex, and that it takes a higher dose 
of CsA to inhibit mPTP in mitochondria isolated from spi-
nal cord compared to cortex (Sullivan et al., 2004). This is 
an important observation as our recent and previous studies 
have focused exclusively on NIM811, which can be used 
at higher doses than CsA. These studies demonstrate that 
NIM811 treatment increases mitochondrial function, spinal 
cord tissue sparing, and functional recovery in a contusion 
injury model (Table 2). 
Future Considerations
One caveat of comparing CsA efficacy is the fact that many 
negative reports go unpublished making it difficult to as-
certain the true impact of CsA treatment in TBI and SCI. 
Regardless, given the detrimental side effects of CsA and 
its vehicle, as well as its immunosuppressive properties, we 
support the idea of targeting mPTP in both TBI and SCI 
using reformulated CsA and non-immunosuppressive CsA 
derivatives such as NIM811. However, some effort should 
go into understanding the impact of targeting mPTP forma-
tion in cells that are significantly compromised and may not 
survive without intervention. There is evidence that mito-
chondrial dysfunction persists well beyond the acute stages 
following TBI and SCI, and it is not clear whether rescuing 
compromised mitochondria in minimally functioning cells 
is beneficial. For example, the benefit of CsA administration 
seems to follow an inverted U-shape highlighting the need 
Table 2 Experimental studies testing the efficacy of CsA or NIM811 in the treatment of traumatic SCI
Study
SCI model/
species Route Dose/time Outcome
Diaz-Ruiz et al. 
(1999)
Contusion/rat i.p. CsA: 2.5 mg/kg every 12 hours for 1 or 3 days CsA significantly decreased lipid peroxidation and 
improved motor scores on the Tarlov scale.
Rabchevsky et al. 
(2001)
Contusion/rat i.p./pump CsA: 20 mg/kg/15 minutes post-injury + 2.5 
mg/kg/day pump
CsA had no effect on any outcome measure.
Ibarra et al. 
(2003)
Compression/
rat
Oral, i.p. CsA: 5 mg/kg/12 hours starting 48 hours 
before injury until study endpoint. 2.5 mg/kg 
i.p. first 3 days after injury.
CsA inhibited demyelination and death of descending 
rubrospinal tract axons, and also improved motor recovery 
(BBB scale). 
McEwen et al. 
(2007)
Contusion/rat i.p. NIM811: 40 mg/kg/15 minutes pre-injury NIM811 significantly improved mitochondrial function 
and decreased mitochondrial free radical production.
Ibarra et al. 
(2007)
Transection/
rat
Oral CsA: 2.5 mg/kg 6 hours and 12 hours post 
followed by 5 mg/kg daily until study endpoint
CsA increased axonal growth and GAP-43 expression, but 
axons were not functional and there was no behavioral 
recovery.
Ravikumar et al. 
(2007)
Contusion/rat Oral NIM811:20 mg/kg/1, 12, and 24 hours post-
injury
NIM811 significantly reduced cytochrome c and 
fragmented DNA, and increased spared gray and white 
matter.
Springer et al. 
(2018)
Contusion/rat Oral NIM811: 10, 20, or 40 mg/kg at 1, 12, and 24 
hours post-injury
NIM811 significantly improved open field locomotor 
performance (10 mg/kg). 20 and 40 mg/kg significantly 
improved return of reflexive bladder control and tissue 
sparing.
Chen et al. (2018) Contusion/rat Pump CsA: 4 mg/kg/daily for 7, 14, or 21 days CsA decreased apoptosis and cytokine levels. Preserves 
mitochondrial morphology and prevents diffuse axonal 
injury.
SCI: Spinal cord injury; CsA: cyclosporin A; i.p.: intraperitoneal; BBB: Basso Beattie Bresnahan.
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for robust therapeutic window data in preclinical studies. It 
also is not clear what cellular energy demands are placed on 
surrounding cells in order to maintain minimally functioning 
cells that might die off in the absence of mPTP targeted drugs. 
Finally, the current mPTP drugs do not exhibit any cell spec-
ificity, which might prove detrimental if treatment promotes 
survival and life span of pro-inflammatory and destructive 
microglia, neutrophils, macrophages, and astrocytes.
In conclusion, there is compelling evidence that targeting 
the mPTP with CsA or NIM811 limits secondary injury and 
promotes functional recovery after TBI and SCI. Future 
studies examining the therapeutic potential of this strategy 
will rely, in part, on 1) identification of other CsA analogues 
or other compounds that selectively target the mPTP, 2) 
replication of existing studies using identical methodologies, 
and 3) examination of mPTP targeted drugs in other species 
and other injury models in which mPTP is known to occur.
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